James Noble

James Noble

Chairman of the Board of Directors

Born 1959. Chairman of the Board of Directors since 2020.

M.A. from the University of Oxford.

Other appointments:

Board member of Adaptimmune and Chairman of the Board of two private UK-based cancer research companies

Previous appointments:

Co-founder and CEO of Adaptimmune and Immunocore. Board member and Deputy Chairman of GW Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. Chairman and CEO of Avidex, which was acquired by Medigene. Other positions as Board member include companies, such as Medigene, PowderJect Pharmaceuticals and CuraGen Corporation.

Holds 28,000 shares, and bonds of a nominal value of SEK 2,500,000.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

 


Staffan Lindstrand

Staffan Lindstrand

Board member

Born 1962. Board member since 2002.

M.Sc. in Engineering.

Other appointments:

Partner of HealthCap since 1997, Board member of HealthCap AB, Doctrin AB, Elsa Science AB, GET.ON Institut für Online Gesundheitstrainings GmbH, and The Swedish Association of Exchange-listed companies.

Previous appointments:

Ten years in investment banking.

Holds 26 933 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Charlotte Hansson

Charlotte Hansson

Board member

Born 1969. Board member since 2020.

MSc. in Business Administration from Handelshögskolan at the University of Gothenburg.

Other appointments:

CFO at Tele 2 AB.

Previous appointments:

CFO at Systembolaget AB, CFO & Executive VP at Cision AB, CFO at Addici AB and various positions within business controlling at Modern Times Group.

Holds 5,500 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Henrik Kjaer Hansen

Henrik Kjaer Hansen

Board member

Born 1976. Board member since 2018.

BSc. in Business Administration and a MSc. in Applied Economic and Finance at Copenhagen Business School.

Other appointments: 

Senior Director, Principal Investments, Novo Holdings A/S. Board member of Xellia Pharmaceutical.

Previous appointments:

Senior Vice President in Moelis & Co. in London, focusing on healthcare M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO, all in London.

Does not hold any shares in Orexo.1

Independent in relation to Orexo and its management, but dependent in relation to the company’s largest shareholders.


Christine Rankin

Christine Rankin

Board member

Born 1964. Board member since 2022.

BSc. in Business Administration and Economics from Stockholm University

Other appointments:

Board member at CoinShares International Ltd and SVP Corporate Control at Veoneer Inc.

Previous appointments:

Board member at Adventure Box Technology AB and at Technopolis Plc, CFO at Cherry AB, interim CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and Partner/Head of the US Capital Markets group in Sweden at PwC.

Holds 2,675 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Michael J Matly

Board member

Born 1981. Board member since 2022.

MBA from Harvard Business School, Medical Doctorate from Mayo Clinic College of Medicine, and Bachelor of Science from Cornell University.

Other appointments:

Co-Founder and Managing Director at 111° West Capital. 

Previous appointments:

Managing Director at Montreux Growth Partners and Director within Business Development and Investments at Mayo Clinic.

Holds 2,820 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Mary Pat Christie

Mary Pat Christie

Board member

Born 1963. Board member since 2019.

MBA.

Other appointments:

Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies. 

Previous appointments:

Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Christie was also the founder of Mend- ham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank.

Holds 3,965 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.


Fred George Wilkinson

Fred George Wilkinson

Board member

Born 1956. Board member since 2019

MBA., B.Sc. Pharmacy

Other appointments:

Board member of Alter Pharma Group.

Previous appointments:

Chief Executive Officer and Board member of Impax Laboratories, Inc., President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan), President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corporation, Inc.

Holds 5,200 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

As of July 31, 2022


Nikolaj Sørensen

Nikolaj Sørensen

President and CEO

Born 1972. President and CEO since 2013, employed since 2011.

B.Sc., and M.Sc., Copenhagen Business School, Denmark.

Other appointments:

Member of the Board, Bioservo Technologies AB, Moberg Pharma AB and Gesynta Pharma AB.

Previous appointments:

Senior management positions at Pfizer Inc. with a focus on commercialization in Europe and Chairman of the Board and Managing Director at Pfizer AB. Prior to Pfizer management consultant at Boston Consulting Group (BCG), leading several projects within M&A, commercial transformation, and turn-arounds.

Holds 121,605 shares and stock options/share awards entitling to 362,544 shares.1


Robert A. DeLuca

Robert A. DeLuca

President Orexo US Inc.

Born 1961. President of Orexo US Inc. since 2013

R.Ph.

Other appointments:

Member of the St. John’s College of Pharmacy Dean’s Advisory Board, American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations.

Previous appointments:

Extensive experience establishing commercial opera- tions in the US with a combined background in market access, marketing, and sales. Has held leadership positions at multinational pharmaceutical companies including Sanofi-Aventis, Schering Plough, Berlex and Pharmacia, and most recently served as Chief Commercial Officer at Archimedes Pharma- ceuticals.

Holds 8,568 shares and stock options/share awards entitling to 185,889 shares.1


Fredrik Järrsten

Fredrik Järrsten

EVP and Chief Financial Officer

Born 1967.

B.Sc. and M.Sc. majoring in Accounting and Finance at the Stockholm School of Economics, Sweden, and International Business at the University of Michigan – Stephen M. Ross School of Business, US.

Previous appointments:

CFO at Vivesto AB, 2021-June 2022. CFO and deputy Chief Executive Officer at Karolinska Development AB, 2018-2020 and as CFO at Bactiguard AB, 2014-2017. Prior to holding various positions as CFO Fredrik Järrsten served as Director Business Development at Aleris AB, 2006-2013. Additionally Fredrik Järrsten has worked as Investment Manager at Litorina Kapital and within Corporate Finance at Lazard and SEB Enskilda.

Holds 10,500 shares and stock options/share awards entitling to 103,200 shares.1


Dennis Urbaniak

Dennis Urbaniak

EVP Digital Therapeutics

Born 1969. EVP Digital Therapeutics since 2019.

Monmouth University, US, BS Business Administration/Marketing/English

Other appointments:

Member of HIMSS (Healthcare Information and Management Systems Society)

Previous appointments:

Chief Digital Officer, Havas Health & You, Chief Executive Officer, Havas Health Plus. Prior to Havas Health & You, Managing Director Accenture Digital Life Sciences Analytics and Janssen Client Account Lead. Before joining Accenture, twenty years at Sanofi in various sales and marketing roles.

Holds 20,000 shares and stock options/share awards entitling to 157,203 shares.1


Cecilia Coupland

Cecilia Coupland

VP and Head of Operations

Born 1976. SVP and Head of Operations since 2019, employed since 2006.

MSc in Chemical Engineering, Uppsala University, Sweden.

Previous appointments:

Head of Supply Chain & Planning at Orexo since 2014 and prior to that extensive experience of global pharmaceutical manufacturing and supply chain management, as well as drug development and project management, from various key positions at AstraZeneca and Orexo AB.

Holds 11,014 shares stock options/share awards entitling to 134,699 shares.1


Robert Rönn

Robert Rönn

SVP and Head of R&D

Born 1976. SVP and Head of R&D since 2019, employed since 2007.

MSc in Chemical Engineering and PhD in Medicinal Chemistry, Uppsala University, Sweden.

Previous appointments:

Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience
of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.

Holds 7,121 shares and stock options/share awards entitling to 140,422 shares.1


1 As of July 31, 2022

Note: Alloted long-term incentive programs with vesting terms in accordance with approval from Annual General Meeting.